Type 2 & other diabetes

Emergency Hospitalization, Amputation, and Survival After Charcot Neuro-Osteoarthropathy Diagnosis in People With Diabetes: A Regional Registry-Based Cohort Study

Diabetes CarePublished Retrospective cohort study

Authors' conclusion

Adverse outcomes in CNO were frequent and occurred early after diagnosis, with high rates of emergency hospitalization, amputation, and death.

Study context

Population
Adults with diabetes and a first recorded Charcot neuro-osteoarthropathy (CNO) diagnosis, NHS Greater Glasgow and Clyde, Scotland (2015–2024); mean age 59 years, 67% menfrom 127,513 adults with DM
Participants
140 adults
Outcome
Adverse outcomes after CNO diagnosis
Follow-up
median 4.6-year follow-up
Methodological detailsregional, registry-based, linked routinely collected health care data
  • Regional
  • Registry-based
  • Linked routinely collected health care data

Main finding

As reported in the abstract

Emergency admission
123 (87.9%)
Lower-extremity amputation (minor or major)
44 (31.4%)
Died
53 (37.9%)
Estimated 5-year survival
67%
5-year amputation-free survival
44% (median 4.04 years)

Observational data: associations, not effects.

Further findings

Associations with clinical characteristics

Estimate
High or active foot-risk statusIndependently associatedsubdistribution HR for lower-extremity amputation 8.52 (95% CI 2.05–35.45)
High or active foot-risk statusIndependently associatedHR for shorter amputation-free survival 2.09 (95% CI 1.15–3.80)
Older ageIndependently associatedHR for mortality 3.04 (95% CI 1.50–6.16)
Advanced CKD (stages 4 and 5) was associated with higher risk across outcomes

Original publication

Emergency Hospitalization, Amputation, and Survival After Charcot Neuro-Osteoarthropathy Diagnosis in People With Diabetes: A Regional Registry-Based Cohort Study. Diabetes Care. Published 28 July 2026. doi:10.2337/dc26-0373

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.